Author

D. T. Curiel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 5 Organism:mouse· 4 Research Focus:drug response / drug discovery· 3 Organism:rat· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:non-human primate· 1

Frequent Co-Authors

I. P. Dmitriev· 4 shared M. S. Diamond· 4 shared A. O. Hassan· 3 shared B. Ying· 3 shared D. H. Fremont· 3 shared J. B. Case· 3 shared E. A. Kashentseva· 2 shared E. Kashentseva· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

I. P. Dmitriev

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates

M. Gagne, B. J. Flynn, S. F. Andrew, D. R. Flebbe, A. Mychalowych, E. Lamb, M. E. Davis-Gardner, M. R. Burnett, L. A. Serebryannyy, B. C. Lin, L. Pessaint, J.-P. M. Todd, Z. E. Ziff, E. Maule, R. Carroll, , M Suthar

This study shows that mucosal adenoviral-vectored vaccines provide durable protection against XBB.1.16 infection in nonhuman primates, outperforming intramuscular boosting in reducing virus replication in both upper and lower airways.

bioRxiv · Nov 6, 2023 · PreprintImmunology

A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamsters

B. Ying, T. L. Darling, P. Desai, C.-Y. Liang, I. P. Dmitriev, N. Soudani, T. L. Bricker, E. A. Kashentseva, H. H. Harastani, A. G. Schmidt, D. T. Curiel, A. C. M. Boon, M. S. Diamond

This paper shows a bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 in mice and hamsters through mucosal immunity, despite poor serum neutralizing antibody responses.

bioRxiv · May 4, 2023 · PreprintMicrobiology

An intranasal vaccine durably protects against SARS-CoV-2 variants in mice

A. O. Hassan, S. Shrihari, M. J. Gorman, B. Ying, D. Yuan, S. Raju, R. E. Chen, I. P. Dmitriev, E. Kashentseva, L. J. Adams, P.-Y. Shi, D. H. Fremont, D. T. Curiel, G. Alter, M. S. Diamond

This study shows that an intranasal vaccine provides durable protection against SARS-CoV-2 variants in mice, including emerging strains like B.1.351 and B.1.1.28.

bioRxiv · May 8, 2021Microbiology

A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques

A. O. Hassan, F. Feldmann, H. Zhao, D. T. Curiel, A. Okumura, T.-L. Tang-Huau, J. B. Case, K. Meade-White, J. Callison, J. Lovaglio, P. W. Hanley, D. P. Scott, D. H. Fremont, H. Feldmann, M. S. Diamond

A single intranasal dose of ChAd-SARS-CoV-2-S vaccine protects against SARS-CoV-2 infection in rhesus macaques by inducing neutralizing antibodies and T cell responses.

bioRxiv · Jan 26, 2021Microbiology

A single intranasal dose of chimpanzee adenovirus-vectored vaccine confers sterilizing immunity against SARS-CoV-2 infection

A. O. Hassan, N. M. Kafai, I. P. Dmitriev, J. M. Fox, B. Smith, I. B. Harvey, R. E. Chen, E. S. Winkler, A. W. Wessel, J. B. Case, E. Kashentseva, B. T. McCune, A. L. Bailey, H. Zhao, L. A. VanBlargan, , M. S. Diamond

A single intranasal dose of ChAd-SARS-CoV-2-S vaccine prevents SARS-CoV-2 infection and likely confers sterilizing immunity in mice.

bioRxiv · Jul 16, 2020 · PreprintMicrobiology

MSCs Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma

M. Chastkofsky, K. C. Pituch, H. Katagi, L. Ilut, T. Xiao, Y. Han, A. M. Sonabend, D. T. Curiel, E. R. Bonner, J. Nazarian, C. Horbinski, C. D. James, A. Saratsis, R. Hashizume, M. S. Lesniak, I. V. Balyasnikova

This study shows that mesenchymal stem cells can deliver oncolytic virotherapy to DIPG tumors, significantly improving survival when combined with radiotherapy in preclinical models.

bioRxiv · May 9, 2020Cancer Biology